G.ST Antivirals, a developer of broad-spectrum antivirals against respiratory tract infections, has appointed Ronald Bruce Turner as chief medical officer. Dr Turner will oversee the Austrian company’s current clinical development programme. The company’s lead asset is a broad-spectrum antiviral nasal spray containing 2-Deoxy-D-glucose. It aims to treat rhinoviruses and more severe respiratory diseases in vulnerable people and prevent diseases caused by other agents, such as coronaviruses.
Dr Turner is a former professor of paediatric infectious diseases and an associate dean for clinical research at the University of Virginia, US. He holds a BSc in chemistry from Southern Illinois University and his MD from the Southern Illinois University School of Medicine, both in the US.
G.ST Antivirals announced the appointment on 9 April 2024.
Copyright 2024 Evernow Publishing Ltd.